The Global Market for Adjunctive Therapies in Cancer
Adjunctive therapies are not only vital to the success of cancer treatments, enhancing compliance and outcomes, but they are also a dynamic area of research and development in a variety of disciplines from drug delivery to biologics. It also happens to be the largest portion of the overall cancer therapeutics market.
This report provides the reader with a comprehensive analysis of the worldwide market for therapeutics to treat and manage symptoms in cancer patients. Market information, including market size and growth, is provided for 2003 to 2010 on various product subcategories included in the major segments:
- antinauseants and antiemetics
- pain management
- blood modifiers
- infection control
- other therapies.
In addition, competitive market share and a four-region geographic breakdown are provided for the base year 2005. The study also covers issues and trends affecting the market, research and development pipelines, demographics, cancer statistics, the epidemiology of side effects, and more.
Table of Contents
Chapter one: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting the Global Market
- Leading Competitors
Chapter Two: Introduction
- Overview of Cancer
- Biology of Cancer
- Treatments and Symptoms
- Chemotherapy
- Radiation Therapy
- Oral
- Rectal
- Transdermal and Nasal
- Intravenous or Subcutaneous
Chapter three: Issues and Trends
- Overview
- Geographical Trends
- United States
- European Union
- Japan
- Regulatory Authorities
- Clinical Trials
- New Indications
- Lifestyle and Social Issues
- Barriers to Adjunctive Therapies
- Drug Delivery Advancements
- Pain Management Measures
- Oxycontin Issues
- Cancer-Related Fatigue Issues
- Individualized Chemotherapy
- Chemotherapy and Memory Loss
chapter Four: Antinauseants and Antiemetics
- Overview
- Products
- Serotonin Receptor Antagonists
- Phenothiazines
- Metoclopramide and Other Drugs
- Drug Delivery Methods for Antinauseants and Antiemetics
- Research and Development
- Market Overview
- Competitive Analysis
chapter Five: Pain Management
- Overview
- Pain Pathways
- Primary Cancer Pain
- Breakthrough Cancer Pain
- Cancer Pain Delivery Methods
- Oral
- Oral Transmucosal
- Parenteral
- Transdermal
- Rectal
- Intranasal
- Description of Products
- Primary Cancer Pain Medications
- Non-Narcotic Analgesics
- Narcotic Analgesics
- Breakthrough Cancer Pain Medications
- Antidepressants
- Anticonvulsants
- Corticosteroids
- Bisphosphonates and Calcitonins
- Radiopharmaceuticals
- Other
- Research and Development
- Market Overview
- Competitive Analysis
chapter six: Biological Response Modifiers
- Overview
- Description of Products
- Hematopoietic Growth Factors
- Granulocyte Colony-Stimulating Factor (G-CSF)
- Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF)
- Epoetin Alpha
- Darbepoetin Alfa
- Epoetin Beta
- Human keratinocyte growth factor
- Cytomodulatory Agents
- Research and Development
- Market Overview
- Competitive Analysis
- Description of Products
chapter seven: Infection Control
- Overview
- Description of Products
- Anti-Bacterials and Antivirals
- Antifungals
- Research and Development
- Market Overview
- Competitive Analysis
chapter eight: Other Adjunctive Therapies
- Overview
- Fatigue
- Anorexia/Cachexia/Weight Loss
- Diarrhea
- Constipation
- Alopecia (Hair Loss)
- Radiation-Induced Dermatitis
- Other
- Fatigue
- Anorexia/Cachexia/Weight Loss
- Diarrhea
- Constipation
- Hair Loss
- Radiation-Induced Dermatitis
- Research and Development
- Market Overview
- Competitive Analysis
Chapter Nine: Market Summary
- Overview
- Market Size
- Competitive Analysis
- Market Analysis
chapter Ten: Company Profiles
- Introduction
- Competitive Summary
- Abbott Laboratories
- Amgen, Inc.
- Bayer Corp.
- Cephalon , Inc
- Chugai Pharmaceutical Company Ltd.
- Eli Lilly & Co.
- GlaxoSmithKline plc
- Johnson & Johnson
- Novartis Pharmaceuticals Corp.
- Pfizer, Inc.
- Roche Group
- Sanofi -Aventis
APPENDIX: Company Directory
List of Exhibits
Chapter one: Executive Summary
- Table 1-1: Cancer Incidence and Deaths as a Percentage to Population by Selected Country/Region 2005
- Table 1-2: Summary Table: The World Market for Adjunctive Therapies in Cancer Revenues and Growth Rate 2003-2010Figure 1-1: Summary Figure: The World Market for Adjunctive Therapies in Cancer 2003-2010
Chapter Two: Introduction
- Table 2-1: List of Cancers
- Table 2-2: Side Effects Associated with ChemotherapyTable 2-3: Side Effects Associated with Radiation TherapyTable 2-4: Population by Country 2003-2010Figure 2-1: Population by Major Market Country 2005 vs. 2010Table 2-6: Cancer Incidence and Mortality by Major Market Country 2005Figure 2-3: Cancer Incidence by Major Market Country 2005Figure 2-4: Cancer Deaths by Major Market Country 2005Table 2-8: Cancer Incidence and Deaths as a Percentage to Population by Selected Major Market Country/Region
chapter Four: Antinauseants and Antiemetics
- Figure 4-1: Incidence of Emesis in Cancer Patients
- Table 4-1: Chemotherapy Agents and Level of Emetic Potential
- Table 4-2: Time Course of Selected Products in Nausea and Vomiting
- Table 4-3: Selected Prescription Antinauseants/Antiemetics by Available Delivery Method
- Table 4-4: Antinauseants and Antiemetics in Development for Treatment ofCancer related Nausea and Vomiting
- Table 4-5: The Adjunctive Antinauseant and Antiemetic Market 2003-2010
- Figure 4-1: The Adjunctive Antinauseant and Antiemetic Market 2003-2010
- Table 4-6: The Adjunctive Antinauseant and Antiemetic Market, EstimatedSales by Geographic Region, 2005
- Figure 4-2: The Adjunctive Antinauseant and Antiemetic Market by Geographic Region, 2005
- Table 4-7: Leading Suppliers’ Revenues and Share of the Antinauseants and Antiemetics Segment 2005
- Figure 4-3: Leading Suppliers’ Shares of the Antinauseants and Antiemetics Segment 2005
chapter Five: Pain Management
- Figure 5-1: Incidence of Pain in Cancer Patients
- Table 5-1: The World Health Organization Three-Step Analgesic Ladder
- Table 5-2: Selected Prescription Non-Narcotic Analgesics by Available Delivery Method
- Table 5-3: Selected Over-the-Counter Non-Narcotic Analgesics by AvailableDelivery Method
- Table 5-4: Selected Prescription Narcotic Analgesics by Available DeliveryMethod
- Table 5-5: Selected Prescription Antidepressants Used for Cancer Pain byAvailable Delivery Method
- Table 5-6: Selected Prescription Anticonvulsants Used for Cancer Pain byAvailable Delivery Method
- Table 5-7: Selected Prescription Corticosteroids Used for Cancer Pain byAvailable Delivery Method
- Table 5-8: Selected Prescription Bisphosphonates and Calcitonins Used forCancer Pain by Available Delivery Method
- Table 5-9: Selected Prescription Radiopharmacuticals Used for Cancer Pain by Available Delivery Method
- Table 5-10: Pain Management Products in Development for Treatment of Cancer Related Pain
- Table 5-3: The Adjunctive Pain Management Market 2003-2010
- Figure 5-1: The Adjunctive Pain Management Market 2003-2010
- Table 5-4: The Adjunctive Pain Management Market, Estimated Sales by Geographic Region, 2005
- Figure 5-2: The Adjunctive Pain Management Market by GeographicRegion, 2005
- Table 5-5: Leading Suppliers’ Revenues and Shares of the Cancer PainManagement Segment 2005
- Figure 5-3: Leading Suppliers’ Shares of the Cancer Pain ManagementSegment 2005
chapter six: Biological Response Modifiers
- Figure 6-1: Frequency of Bone Marrow Suppression in Cancer Patients
- Table 6-1: Selected Biological Response Modifiers and Available DeliveryMethod
- Table 6-2: Biological Response Modifiers in Development for Treatment ofCancer Related Infection
- Table 6-3: The Adjunctive Biological Response Modifier Market 2003-2010
- Figure 6-2: The Adjunctive Biological Response Modifier Market 2003-2010
- Table 6-4: The Adjunctive Biological Response Modifier Market, EstimatedSales by Geographic Region, 2005
- Figure 6-3: The Adjunctive Biological Response Modifier Market, Market by Geographic Region, 2005
- Table 6-5: Leading Suppliers’ Revenues and Shares of the Biological Response Modifiers Segment 2005
- Figure 6-4: Leading Suppliers’ Market Share of the Biological ResponseModifiers Segment 2005
chapter seven: Infection Control
- Table 7-1: Common Infection Sites and Organisms
- Figure 7-1: Frequency of Infection in Cancer Patients
- Table 7-2: Selected Prescription Antibacterial and Antiviral Agents and Available Delivery Method
- Table 7-3: Selected Prescription Antifungals and Available Delivery Method
- Table 7-4: Anti-Infective Agents and Antifungals in Development forTreatment of Cancer related Infection
- Table 7-3: The Adjunctive Infection Control Market 2003-2010Figure 7-1: The Adjunctive Infection Control Market 2003-2010
- Table 7-4: The Adjunctive Infection Control Market Estimated Sales byGeographic Region, 2005
- Figure 7-2: The Adjunctive Infection Control Market by GeographicRegion, 2005
- Table 7-5: Leading Suppliers’ Revenues and Shares of the Infection Control Segment 2005
- Figure 7-3: Leading Suppliers’ Market Shares of the Infection ControlSegment 2005
chapter eight: Other Adjunctive Therapies
- Figure 8-1: Frequency of Fatigue in Cancer Patients
- Figure 8-2: Incidence of Anorexia/ Cachexia/Weight Loss in CancerPatients
- Figure 8-3: Incidence of Diarrhea in Cancer Patients
- Figure 8-4: Incidence of Constipation in Cancer Patients
- Table 8-1: Selected Chemotherapy Agents and Level of Hair Loss Potential
- Figure 8-5: Frequency of Hair Loss in Cancer Patients
- Figure 8-6: Prevalence of Other Conditions in Cancer Patients (Sexual/Reproductive, Heart, Liver, Lung, Nerve, Kidney/Urinary Damage)
- Table 8-2: Selected Prescription and Non-prescription Products to Minimize Symptoms of Fatigue in Cancer Patients and Their AvailableDelivery Method
- Table 8-3: Selected Prescription Products for the Treatment of Anorexia/Cachexia in Cancer Patients and Available Delivery Method
- Table 8-4: Selected Prescription and Non-prescription Products for theTreatment of Diarrhea in Cancer Patients and Available Delivery Method
- Table 8-5: Selected Prescription and Non-prescription Products for theTreatment of Constipation in Cancer Patients and AvailableDelivery Method
- Table 8-6: Selected Prescription and Non-prescription Products for theTreatment of Radiation-induced Dermatitis
- Table 8-7: Other Adjunctive Therapies in Development for Treatment ofCancer
- Table 8-8: The Adjunctive Therapy Other Products Market 2003-2010
- Figure 8-7: The Adjunctive Therapy Other Products Market 2003-2010
- Table 8-9: The Adjunctive Therapy Other Products Market, Estimated Sales by Geographic Region, 2005
- Figure 8-8: The Adjunctive Therapy Other Products Market by Geographic
- Region, 2005
Chapter Nine: Market Summary
- Table 9-1: The World Market for Adjunctive Therapies in Cancer 2003-2010
- Figure 9-1: The World Market for Adjunctive Therapies in Cancer 2003-2010
- Table 9-2: The Global Market for Adjunctive Therapies in Cancer byType, 2003-2010
- Figure 9-2: The World Market for Adjunctive Therapies in Cancer Revenues by Type 2003-2010
- Figure 9-3: The World Market for Adjunctive Therapies in Cancer Estimated Market Share by Product Type 2005
- Table 9-5: Leading Suppliers, Products, and Segments of Participation 2005
Other users found this report page using the following search terms: supportive care cancer oncology antinauseants nausea vomiting antiemetics pain infection control neutropenia anemia market cancer size global antiemetic adjunctive cachexia antiemetics therapies therapy
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.